在阿尔茨海默氏症和血管痴呆症之间,中央和外围类甲醇胺的不同参与
Xiao-Yue Hong1, Siwei Li1, Tian Li2
1Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan, 430071, Hubei, China.
Heliyon
|October 14, 2024
概括
这项研究揭示了catecholamine在阿尔茨海默氏症 (AD) 和血管痴呆症 (VaD) 中的不同作用. 阿尔茨海默病涉及中央多巴胺和上腺素,而瓦尔茨海默病与外围类甲醇胺激增有关.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 甲基荷胺在神经退行性疾病中起着至关重要的作用.
- 阿尔茨海默氏症 (AD) 和血管痴呆症 (VaD) 是不同的认知功能障碍,其含有不清楚的甲醇胺.
- 了解不同类甲醇胺的不同作用对于有针对性的疗法至关重要.
研究的目的:
- 调查中央和外围类甲醇胺在阿尔茨海默病 (AD) 和血管痴呆症 (VaD) 中的差异性参与.
- 为了比较AD和VaD的已建立的动物模型中的甲基荷胺概况.
主要方法:
- 使用三重转基因AD (3xTg-AD) 小鼠和通过两血管封闭 (2VO) 在老鼠的慢性大脑低输液 (CCH) 作为AD和VaD模型.
- 在血清和大脑区域使用液态染色学-并体质谱法 (LC-MS/MS) 的量化甲基胺 (多巴胺,上腺素,上腺素) 和代谢物.
主要成果:
- 早期的AD模型显示高海马体多巴胺和皮质/体皮层上腺素/上腺素.
- CCH诱导的VaD模型主要影响中央诺亚上腺系统,而不是多巴胺.
- 在VaD模型中观察到血清catecholamines的增加,但在AD模型中没有.
结论:
- 不同的甲醇胺表达表明在AD和VaD中存在不同的病原体.
- 周围类甲基荷胺激增可能会导致VaD的发展.
- 针对外围类甲基醇胺可以为VaD提供一种保护策略.
相关概念视频
01:26Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
01:22Alzheimer's Disease: Treatment
166
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
166
01:30Dementia
97
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
97
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
106
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
106
01:25Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K
01:37Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K